Tomer Shlomi, PhDTechnion Institute (Israel) Targeting ovarian cancer via MTAP synthetic lethality Ovarian cancer cells are genetically unstable. A deletion of the gene MTAP, which is involved in methionine metabolism, is found in 3-15% of ovarian tumors. As a result, affected ovarian cancer cells have lost a functional enzyme for metabolizing old proteins which is […]
Read More
Keren Levanon, MD/PhDSheba Fund for Health Service and Research2019 Pilot Study Award Microbiome profiling unveils metabolic vulnerabilities of BRCA mutated ovarian cancer Recent studies have shown that fallopian tubes and other genital track tissues that were previously thought to be sterile actually contain bacteria. These bacteria are believed to cause chronic inflammation which can lead […]
Read More
Cecil Han, PhDGeorgetown University Understanding and Targeting Mitochondrial Heterogeneity in Ovarian Cancer High grade serous ovarian cancers are very complex and variable, making them difficult to treat. One source of this variability may be in the mitochondria, a cellular component known as the “powerhouse”, of ovarian cancer cells. Studies have shown that the variability in […]
Read More
Martin Matzuk, MD, PhDBaylor College of Medicine 2013 Challenge Grant Award Recipient Molecular Imaging of the Dicer/Pten Mouse Model Tumor Microenvironment Dr. Matzuk’s project will use Dicer-Pten mutant mice, which closely model human high-grade serous carcinoma with tumors arising in the fallopian tubes. A state-of-the-art tissue-based mass spectrometry imaging platform will provide the approach for […]
Read More